An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS).

NCT07546110 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL: NK042
DRUG: ofatumumab

Sponsor

The Affiliated Hospital of Xuzhou Medical University